Brain-derived neurotrophic factor, neutrophils and cysteinyl leukotriene receptor 1 as potential prognostic biomarkers for patients with colon cancer

• The tumor microenvironment has been recognized as a complex network in which immune cells play an important role in cancer progression. We found significantly higher CD66b neutrophil expression in tumor tissue than in matched normal mucosa in the Malmö colon cancer (CC) cohort and poorer survival of stage I-III patients with high CD66b expression. Additionally, mice lacking CysLT1 R expression (cysltr1−/− ) produce less brain-derived neurotrophic factor (BDNF) compared to WT mice and Montelukast (a CysLT1 R antagonist)-treated mice also reduced BDNF expression in a mouse xenograft model with human SW480 CC cells. CD66b and BDNF expression was significantly higher in patient tumor tissues than in the matched normal mucosa. The univariate Cox PH analysis yielded CD66b and BDNF as an independent predictor of overall survival, which was also found in the public TCGA-COAD dataset. We also discovered a strong positive correlation between CD66b, BDNF and CysLT1 R expression in the Malmö CC cohort and in the TCGA-COAD dataset. Our data suggest that CD66b/BDNF/CysLT1 R expression as a prognostic combined biomarker signature for CC patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

BDNF

Colon cancer

CysLT

LTD

Montelukast

Neutrophils

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)